Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)

ACE OncoCast

Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with collaboration between surgeons, medical oncologists, radiation oncologists, pathologists and other specialists.

Bladder preservation is an alternative to cystectomy for patients deemed unfit for surgery. The MDT board should develop a treatment strategy tailored to meet the needs of patients seeking bladder preservation. The management of locally advanced operable bladder cancer and the role of pre and postoperative systemic treatments have become increasingly intricate. Neoadjuvant cisplatin-based chemotherapy has been the standard of care for some years. Adjuvant immunotherapy has now emerged as a new standard of care for postoperative patients with high risks. Nonetheless, there remain gaps that need to be addressed for practicing oncologists to gain an in-depth understanding of individualized treatment strategies for MIBC.

Let's watch the recorded video on 'Frequently Asked Questions (FAQs) for MIBC' to gain comprehensive insights from leading experts – Dr. Francisco X. Real from National Cancer Research Center of Spain, Dr. Félix Guerrero Ramos from Hospital Universitario 12 de Octubre in Madrid, Dr. Natalia Carballo and Dr. Enrique Grande from MD Anderson Cancer Center Madrid.

Melde dich an, um anstößige Folgen anzuhören.

Bleib auf dem Laufenden mit dieser Sendung

Melde dich an oder registriere dich, um Sendungen zu folgen, Folgen zu sichern und die neusten Updates zu erhalten.

Wähle ein Land oder eine Region aus

Afrika, Naher Osten und Indien

Asien/Pazifik

Europa

Lateinamerika und Karibik

USA und Kanada